| Literature DB >> 35573024 |
Yiguo Liu1, Yingying Zhang1, Xiaoqin Zhang1, Xi Liu1, Yanfang Zhou1, Yun Jin1, Chen Yu1.
Abstract
Objective: Early prediction of long-term outcomes in patients with sepsis-induced cardiorenal syndrome (CRS) remains a great challenge in clinical practice. Herein, we aimed to construct a nomogram and machine learning model for predicting the 1-year mortality risk in patients with sepsis-induced CRS.Entities:
Keywords: cardiorenal syndrome; machine learning; nomogram; prognosis; sepsis
Year: 2022 PMID: 35573024 PMCID: PMC9099150 DOI: 10.3389/fmed.2022.792238
Source DB: PubMed Journal: Front Med (Lausanne) ISSN: 2296-858X
FIGURE 1Flow chart illustrating the patient enrollment in discovery cohort.
FIGURE 2The linear analysis of numeric variables. (A) Basic serum creatinine. (B) Age. (C) Serum MYO levels on day 1. (D) Serum MYO levels on day 3.
FIGURE 3(A) The process of development of nomogram. (B) The process of machine learning methods.
Patient clinical characteristics.
| Variables | Survivors | Non-survivors | Z/χ2 |
|
| Age | 79.00 (64.50,86.00) | 83.00 (72.00,88.00) | –2.358 | 0.018 |
| Male sex | 88 (52.1%) | 97 (56.7%) | 1.314 | 0.252 |
| Department | 10.181 | 0.017 | ||
| ICU | 58 (34.3%) | 52 (30.4%) | ||
| Emergency department | 70 (41.4%) | 55 (32.2%) | ||
| Medical ward | 27 (16.0%) | 52 (30.4%) | ||
| Surgical ward | 14 (8.3%) | 12 (7.0%) | ||
| Infection site | 9.708 | 0.021 | ||
| Respiratory system | 82 (48.5%) | 111 (64.9%) | ||
| Digestive system | 37 (21.9%) | 28 (16.4%) | ||
| Urinary system | 35 (20.7%) | 21 (12.3%) | ||
| Skin and soft tissue | 8 (4.7%) | 9 (5.3%) | ||
| Other | 7 (4.1%) | 2 (1.2%) | ||
| Blood culture | 5.300 | 0.258 | ||
| Negative | 97 (57.4%) | 81 (47.4%) | ||
| Gram-positive | 8 (4.7%) | 15 (8.8%) | ||
| Gram-negative | 25 (14.8%) | 29 (17.0%) | ||
| Fungus | 11 (6.5%) | 9 (5.3%) | ||
| Polymicrobial infection | 28 (16.6%) | 37 (21.6%) | ||
| SBP, mmHg | 120.00 (100.00, 140.00) | 120.00 (105.00, 140.00) | –0.237 | 0.812 |
| DBP, mmHg | 70.00 (60.00, 80.00) | 70.00 (60.00, 80.00) | –0.770 | 0.441 |
| HR | 85.00 (80.00, 99.00) | 86.00 (80.00, 102.00) | –0.438 | 0.661 |
| T, °C | 37.00 (36.50, 38.00) | 37.00 (36.50, 37.50) | –1.874 | 0.061 |
| Pre-existing disease | ||||
| Diabetes | 57 (33.7%) | 54 (31.6%) | 0.178 | 0.673 |
| Hypertension | 108 (63.9%) | 108 (63.2%) | 0.020 | 0.886 |
| CAD | 55 (32.5%) | 59 (34.5%) | 0.146 | 0.702 |
| Stroke | 51 (30.2%) | 65 (38.0%) | 2.321 | 0.128 |
| CKD | 25 (14.8%) | 29 (17.0%) | 0.299 | 0.585 |
| History of tumor | 16 (9.5%) | 13 (7.6%) | 0.379 | 0.538 |
| History of smoking | 28 (16.6%) | 42 (24.6%) | 3.322 | 0.068 |
| Medication history | ||||
| Diuretics | 62 (36.7%) | 77 (45.0%) | 2.448 | 0.118 |
| CCB | 53 (31.4%) | 55 (32.2%) | 0.026 | 0.874 |
| ACEI | 18 (10.7%) | 10 (5.8%) | 2.595 | 0.107 |
| ARB | 48 (28.4%) | 44 (25.7%) | 0.307 | 0.579 |
| β-blocker | 41 (24.3%) | 34 (19.9%) | 0.947 | 0.330 |
| Statin | 45 (26.6%) | 37 (21.6%) | 1.156 | 0.282 |
| Nitrate ester | 36 (21.3%) | 35 (20.5%) | 0.036 | 0.850 |
| Digoxin | 14 (8.3%) | 20 (11.7%) | 1.099 | 0.297 |
| Antiplatelet drug | 59 (34.9%) | 52 (30.4%) | 0.783 | 0.376 |
| Warfarin | 37 (21.9%) | 27 (15.8%) | 2.073 | 0.150 |
| In-hospital treatment | ||||
| Mechanical ventilation | 24 (14.2%) | 68 (39.8%) | 28.146 | <0.001 |
| Vasopressor | 63 (37.3%) | 126 (73.7%) | 45.632 | <0.001 |
| qSOFA | ||||
| ≤2 | 123 (72.8%) | 119 (69.6%) | 0.422 | 0.516 |
| >2 | 46 (27.2%) | 52 (30.4%) | ||
| Total SOFA | 5.00 (3.00, 8.00) | 11.00 (6.00, 13.00) | –8.166 | <0.001 |
| Respiratory system | 0.00 (0.00,2.00) | 0.00 (0.00,3.00) | –5.755 | <0.001 |
| Nervous system | 0.00 (0.00,1.00) | 1.00 (1.00,3.00) | –8.921 | <0.001 |
| Cardiovascular system | 0.00 (0.00,1.00) | 2.00 (0.00,3.00) | –5.917 | <0.001 |
| Liver | 0.00 (0.00,1.00) | 0.00 (0.00,1.00) | –2.049 | 0.040 |
| Coagulation | 1.00 (1.00,2.00) | 1.00 (1.00,2.00) | –1.027 | 0.305 |
| Kidneys | 2.00 (1.00,2.00) | 2.00 (1.00,3.00) | –2.857 | 0.004 |
| Laboratory variables | ||||
| Baseline Scr, umol/L | 93.00 (72.00, 130.50) | 98.00 (74.00, 162.00) | –1.574 | 0.116 |
| Scr on day 1, umol/L | 185.00 (141.00, 260.50) | 189.00 (146.00, 289.00) | –0.753 | 0.452 |
| Scr on day 3, umol/L | 3.600 | 0.308 | ||
| <133 | 73 (43.2%) | 61 (35.7%) | ||
| 133∼177 | 33 (19.5%) | 30 (17.5%) | ||
| 178∼442 | 50 (29.6%) | 60 (35.1%) | ||
| >443 | 13 (7.7%) | 20 (11.7%) | ||
| MYOon day 1, ng/mL | 174.20 (81.60,484.80) | 316.10 (126.60,1055.40) | –3.854 | <0.001 |
| MYO on day 3, ng/mL | 94.10 (49.30,168.90) | 226.90 (90.60,650.00) | –6.709 | <0.001 |
| The rate of change in MYO, % | –49.00 (-73.00, 0.00) | –28.00 (-66.00,24.00) | –2.932 | 0.003 |
| cTnI on day 1, ng/mL | 7.441 | 0.024 | ||
| < 0.03 | 15 (8.9%) | 22 (12.9%) | ||
| 0.03∼0.5 | 105 (62.1%) | 120 (70.2%) | ||
| >0.5 | 49 (29.0%) | 29 (17.0%) | ||
| cTnI on day 3, ng/mL | 0.329 | 0.848 | ||
| <0.03 | 27 (6.0%) | 31 (18.1%) | ||
| 0.03∼0.5 | 110 (65.1%) | 110 (64.3%) | ||
| >0.5 | 32 (18.9%) | 30 (17.5%) |
ICU, intensive care unit; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; T, temperature; CAD, coronary artery disease; CKD, chronic kidney disease; CCB, calcium channel blocker; ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blockers; Serum creatinine, Scr; SOFA, Sequential (Sepsis-related) Organ Failure Assessment; qSOFA, quick SOFA; MYO, myoglobin; cTnI, cardiac troponin I.
Univariate and multivariate analyses for prognostic factors.
| Variables | Category | Univariate analysis | Multivariate analysis | ||
|
|
| ||||
| OR (95% CI) | OR (95% CI) | ||||
| Age | Per year | 1.04 (1.02∼1.06) | 0.000 | 1.08 (1.05∼1.11) | <0.001 |
| Gender | Female | 1 | |||
| Male | 1.21 (0.79∼1.85) | 0.389 | |||
| SBP | Per mmHg | 1.01 (0.99∼1.02) | 0.103 | ||
| DBP | Per mmHg | 1.00 (0.99∼1.02) | 0.550 | ||
| HR | Per minute | 1.00 (0.99∼1.01) | 0.706 | ||
| T, Celsius | Per degrees Celsius | 0.96 (0.87∼1.07) | 0.510 | ||
| Infection site | Respiratory system | 1 | 0.022 | 1 | 0.991 |
| Digestive system | 0.56 (0.32,0.99) | 0.045 | 1.15 (0.53∼2.47) | 0.726 | |
| Urinary system | 0.44 (0.24,0.82) | 0.009 | 0.92 (0.41∼2.06) | 0.839 | |
| Skin and soft tissue | 0.83 (0.31,2.25) | 0.715 | 0.88 (0.22∼3.49) | 0.856 | |
| Other | 0.21 (0.04,1.04) | 0.056 | 1.16 (0.16∼8.08) | 0.878 | |
| Basic disease | |||||
| Diabetes | No | 1 | |||
| Yes | 0.91 (0.58∼1.43) | 0.673 | |||
| Hypertension | No | 1 | |||
| Yes | 0.97 (0.62∼1.51) | 0.886 | |||
| CAD | No | 1 | |||
| Yes | 1.09 (0.70∼1.71) | 0.702 | |||
| Stroke | No | 1 | |||
| Yes | 1.419 (0.90∼2.23) | 0.128 | |||
| CKD | No | 1 | |||
| Yes | 1.17 (0.66∼2.11) | 0.585 | |||
| Diabetes | No | 1 | |||
| Yes | 0.79 (0.37∼1.69) | 0.539 | |||
| History of smoking | No | 1 | 1 | ||
| Yes | 1.64 (0.96∼2.80) | 0.070 | 1.21 (0.59∼2.51) | 0.592 | |
| Medication history | No | ||||
| Diuretics | Yes | 1 | |||
| No | 1.41 (0.92∼2.18) | 0.118 | |||
| CCB | No | 1 | |||
| Yes | 1.04 (0.66∼1.64) | 0.874 | |||
| ACEI | No | 1 | |||
| Yes | 0.52 (0.23∼1.17) | 0.112 | |||
| ARB | No | 1 | |||
| Yes | 0.873 (0.54∼1.41) | 0.579 | |||
| β-blocker | No | 1 | |||
| Yes | 0.78 (0.46∼1.30) | 0.331 | |||
| Statin | No | 1 | |||
| Yes | 0.76 (0.46∼1.25) | 0.283 | |||
| Nitrate ester | No | 1 | |||
| Yes | 0.95 (0.56∼1.60) | 0.850 | |||
| Digoxin | No | 1 | |||
| Yes | 1.47 (0.72∼3.01) | 0.297 | |||
| Antiplatelet drug | No | 1 | |||
| Yes | 0.82 (0.52∼1.28) | 0.376 | |||
| Warfarin | No | 1 | |||
| Yes | 0.67 (0.39∼1.16) | 0.151 | |||
| In-hospital treatment | |||||
| Mechanical ventilation | No | 1 | 1 | ||
| Yes | 3.98 (2.35,6.77) | <0.001 | 3.51 (1.67∼7.40) | 0.001 | |
| Vasopressor | No | 1 | 1 | ||
| Yes | 4.71 (2.97∼7.48) | <0.001 | 2.07 (1.12∼3.83) | 0.020 | |
| qSOFA | ≤ 2 | 1 | |||
| >2 | 1.17 (0.73∼1.87) | 0.422 | |||
| Total SOFA | 1.29 (1.21∼1.37) | <0.001 | 1.24 (1.14∼1.37) | <0.001 | |
| Laboratory variables | |||||
| Baseline Scr, μmol/L | 1.00 (1.00∼1.01) | 0.005 | 1.00 (0.99∼1.01) | 0.108 | |
| Scr on day 1, μmol/L | 1.00 (1.00∼1.00) | 0.118 | 1.00 (0.99∼1.00) | 0.763 | |
| Scr on day 3, μmol/L | < 133 | 1 | 0.311 | 1 | |
| 133∼177 | 1.09 (0.60∼1.98) | 0.783 | 0.61 (0.29∼1.52) | 0.297 | |
| 178∼442 | 1.44 (0.87∼2.38) | 0.161 | 1.68 (0.83∼3.46) | 0.152 | |
| > 443 | 1.84 (0.85∼4.00) | 0.123 | 2.08 (0.72∼6.18) | 0.182 | |
| MYO on day 1, ng/mL | 1.00 (1.00∼1.00) | <0.001 | 1.00 (0.99∼1.00) | 0.867 | |
| MYO on day 3, ng/mL | < 100 | 1 | <0.001 | 1 | 0.036 |
| 100∼500 | 2.23 (1.36∼3.64) | 0.001 | 0.83 (0.41∼1.65) | 0.588 | |
| > 500 | 8.50 (4.19∼17.24) | <0.001 | 3.51 (0.98∼12.55) | 0.054 | |
| The rate of change in MYO, % | 1.00(1.00∼1.01) | 0.012 | 1.61 (1.26∼2.14) | 0.502 | |
| cTnI on day 1, ng/mL | < 0.03 | 1 | 0.026 | 0.81 (0.34∼1.95) | 0.056 |
| 0.03∼0.5 | 0.78 (0.38∼1.58) | 0.489 | 0.36 (0.13∼1.00) | 0.640 | |
| > 0.5 | 0.40 (0.18∼0.90) | 0.026 | 1.00 (0.13∼1.00) | 0.050 | |
| cTnI on day 3, ng/mL | < 0.03 | 1 | 0.849 | ||
| 0.03∼0.5 | 0.87 (0.50∼1.56) | 0.640 | |||
| > 0.5 | 0.82 (0.40∼1.67) | 0.580 | |||
SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; T, temperature; CAD, coronary artery disease; CKD, chronic kidney disease; CCB, calcium channel blocker; ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blockers; Serum creatinine, Scr; SOFA, Sequential (Sepsis-related) Organ Failure Assessment; qSOFA, quick SOFA; MYO, myoglobin; cTnI, cardiac troponin I.
FIGURE 4The Nomogram for prediction of 1-year mortality risk in patients with newly diagnosed sepsis-induced cardiorenal syndrome.
Regression coefficient estimates of the 1-year predictive model.
| Variables | β | SE |
| OR | 95% CI |
| Age, year | 0.073 | 0.013 | <0.001 | 1.076 | 1.048∼1.105 |
| Total SOFA | 0.215 | 0.044 | <0.001 | 1.240 | 1.137∼1.352 |
| Vasopressors | 0.758 | 0.299 | 0.011 | 2.133 | 1.188∼3.831 |
| Mechanical ventilation | 1.280 | 0.365 | <0.001 | 3.598 | 1.760∼7.353 |
| Baseline Scr, umol/L | 0.004 | 0.002 | 0.066 | 1.004 | 1.001∼1.008 |
| MYO on day 3, ng/mL | |||||
| <100 | – | – | 0.002 | – | – |
| 100∼500 | –0.203 | 0.325 | 0.532 | 0.816 | 0.432∼1.542 |
| >500 | 1.286 | 0.444 | 0.004 | 3.618 | 1.517∼8.629 |
| Constant | –8.680 | 1.256 | 0.000 | 0.000 | – |
SOFA, Sequential (Sepsis-related) Organ Failure Assessment; Scr, Scr; MYO, myoglobin.
FIGURE 5The receiver operating characteristic (ROC) curve and calibration curve of nomogram. (A) the ROC curves of the nomogram in discovery cohort. (B) Comparison of AUC between the nomogram and SOFA. (C) The calibration curve of the nomogram. (D) Comparison of the calibration curves between the ideal model, the nomogram and the bias-corrected model.
FIGURE 6The decision analysis curves of the nomogram and SOFA in discovery cohort.
The metrics of different machine learning models.
| Machine learning techniques | Accuracy | Precision | Recall | F1 score | AUC |
| Decision tree | 0.657 | 0.627 | 0.740 | 0.679 | 0.750 |
| SVM | 0.637 | 0.741 | 0.840 | 0.778 | 0.675 |
| Random forest | 0.765 | 0.724 | 0.696 | 0.753 | 0.825 |
| GBDT | 0.716 | 0.691 | 0.760 | 0.724 | 0.775 |
| Xgboost | 0.706 | 0.667 | 0.800 | 0.727 | 0.708 |
| lGBM | 0.716 | 0.684 | 0.780 | 0.729 | 0.797 |
SVM, support vector machine; GBDT, gradient boosted decision tree; Xgboost, extreme gradient boosting; LGBM, light gradient boosted machine.
FIGURE 7The feature importance and the ROC curves of machine learning models. (A) The feature ranking analysis produced by Random Forest. (B) ROC curves of Random Forest. (C) ROC curves of support vector machine (SVM). (D) ROC curves of decision tree. (E) ROC curves of gradient boosted decision tree (GBDT).
FIGURE 8A pruned decision tree for predicting risk stratification of 1-year mortality in sepsis-induced CRS patients.